CSBio CSBio

X
[{"orgOrder":0,"company":"Medis","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla\u00ae","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"SLOVENIA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Medis"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreement announced today, Medis will initially focus on the commercialization of NaMuscla® in the Central and East European countries, namely Croatia, Czech Republic, Hungary, Slovakia, and Slovenia in the first phase.

            Lead Product(s): Mexiletine

            Therapeutic Area: Musculoskeletal Product Name: NaMuscla

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Lupin Ltd

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 09, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY